Skip to main content
Back
VBIZF logo

Viva Biotech Holdings

Data quality: 100%
Overbought
VBIZF
OTC Healthcare Biotechnology
$0.34
$0.00 (0.00%)
Mkt Cap: 724.45M
Day Range
$0.30 $0.34
52-Week Range
$0.18 $0.43
Volume
100
50D / 200D Avg
$0.31 / $0.27
Prev Close
$0.34

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 4.3 0.4
P/B 0.2 2.9
ROE % 4.5 3.7
Net Margin % 8.4 3.9
Rev Growth 5Y % 29.9 10.0
D/E 0.3 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $0.00
$0.00 – $0.00
 840 M 0
FY2028 $0.00
$0.00 – $0.00
 1 B 0
FY2027 $0.16
$0.16 – $0.16
 2.7 B 1

Key Takeaways

Revenue grew 29.94% annually over 5 years — strong growth
ROE of 4.47% is below average
Debt/Equity of 0.34 — conservative balance sheet
Generating 182.32M in free cash flow
P/E of 4.33 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 37.78%

Growth

Revenue Growth (5Y)
29.94%
Revenue (1Y)-7.84%
Earnings (1Y)N/A
FCF Growth (3Y)15.48%

Quality

Return on Equity
4.47%
ROIC3.98%
Net Margin8.42%
Op. Margin13.57%

Safety

Debt / Equity
0.34
Current Ratio1.67
Interest Coverage5.00

Valuation

P/E Ratio
4.33
P/B Ratio0.19
EV/EBITDA3.96
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -7.84% Revenue Growth (3Y) -8.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 29.94% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.99B Net Income (TTM) 167.29M
ROE 4.47% ROA 2.37%
Gross Margin 34.60% Operating Margin 13.57%
Net Margin 8.42% Free Cash Flow (TTM) 182.32M
ROIC 3.98% FCF Growth (3Y) 15.48%
Safety
Debt / Equity 0.34 Current Ratio 1.67
Interest Coverage 5.00 Dividend Yield 0.00%
Valuation
P/E Ratio 4.33 P/B Ratio 0.19
P/S Ratio 0.36 PEG Ratio -0.03
EV/EBITDA 3.96 Dividend Yield 0.00%
Market Cap 724.45M Enterprise Value 1.07B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.99B 2.16B 2.38B 2.10B 696.96M
Net Income 167.29M -116.11M -528.48M 287.55M -386.88M
EPS (Diluted) 0.06 -0.06 -0.28 0.15 -0.25
Gross Profit 687.40M 738.43M 815.68M 650.98M 304.87M
Operating Income 269.59M 192.68M 269.35M 236.90M 115.57M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7.05B 7.45B 7.92B 8.04B 8.15B
Total Liabilities 3.23B 3.76B 4.32B 4.13B 4.40B
Shareholders' Equity 3.80B 3.69B 3.60B 3.91B 3.76B
Total Debt 1.28B 1.90B 2.82B 2.65B 2.97B
Cash & Equivalents 941.58M 1.04B 678.57M 800.95M 2.31B
Current Assets 1.88B 2.03B 1.94B 1.98B 3.35B
Current Liabilities 1.13B 1.53B 2.67B 926.60M 735.67M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#547 of 825
35
Value Defensive Investing (Benjamin Graham)
#59 of 710
63

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026